Transferrin Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Transferrin Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Transferrin</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TF](/genes/tf)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P02787](https://www.uniprot.org/uniprot/P02787)</td>
</tr>
<tr>
<td class="label">PDB ID</td>
<td>[1BP5](https://www.rcsb.org/structure/1BP5), [1JTF](https://www.rcsb.org/structure/1JTF)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~80 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Secreted, extracellular</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Transferrin family</td>
</tr>
<tr>
<td class="label">Iron-binding capacity</td>
<td>2 Fe³⁺ ions per molecule</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Role in Brain Iron Metabolism</td>
</tr>
<tr>
<td class="label">[Tf](/genes/tf)</td>
<td>Transferrin - primary iron transporter</td>
</tr>
<tr>
<td class="label">[TfR1](/genes/tfrc)</td>
<td>Transferrin receptor - cellular uptake</td>
</tr>
<tr>
<td class="label">[DMT1](/genes/slc11a2)</td>
<td>Divalent metal transporter - iron import</td>
</tr>
<tr>
<td class="label">[Ferritin](/genes/ftl)</td>
<td>Iron storage protein</td>
</tr>
<tr>
<td class="label">[FPN](/genes/slc40a1)</td>
<td>Ferroportin - iron export</td>
</tr>
<tr>
<td class="label">[Hepcidin](/genes Hamp)</td>
<td>Iron regulatory hormone</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">5 edges</a></td>
</tr>
</table>
Transferrin (TF) is an 80 kDa iron-binding glycoprotein that plays essential roles in systemic and cellular iron homeostasis. In the nervous system, transferrin is critically important for delivering iron across the [blood-brain barrier](/entities/blood-brain-barrier) (BBB), distributing iron to [neurons](/entities/neurons) and glia, and maintaining iron balance in the brain. Iron dysregulation is a hallmark of numerous neurodegenerative diseases, making transferrin a protein of significant interest in neurobiology. [@crystal1998]
Protein Overview
Structure
Primary Structure
Transferrin is a single polypeptide chain of approximately 679 amino acids organized into two homologous lobes: [@clioquinol2022]
N-lobe (N-terminal): Residues 1-339
C-lobe (C-terminal): Residues 340-679Each lobe contains: [@iron2021a]
- Iron-binding site: Conserved Asp-X-Ser-X-Arg-Lys motif
- Synaptic cleft: Opening for iron binding/release
- Inter-lobe bridge: Flexible hinge region connecting lobes
Three-Dimensional Structure
The crystal structure reveals a bilobal architecture with [1]: [@iron2020]
- Two similar domains: Each lobe folds into two subdomains forming a cleft
- Iron coordination: Each iron is coordinated by four amino acids (two tyrosines, one aspartate, one histidine) plus a carbonate anion
- Conformational changes: Iron binding induces conformational closure of the cleft
Glycosylation
- Two N-linked glycans: Located at Asn-413 and Asn-611
- Sialylation: Contributes to serum half-life and receptor recognition
- Structural role: Carbohydrate moieties stabilize the protein
Normal Function in the Nervous System
Iron Transport Across the Blood-Brain Barrier
The blood-brain barrier represents the primary interface for iron entry into the brain: [@iron2022a]
Cellular pathway: Transferrin-bound iron enters brain endothelial cells via transferrin receptor-mediated endocytosis [2]
Transcytosis: The transferrin-transferrin receptor complex undergoes transcytosis across endothelial cells
Iron release: Endosomal acidification releases iron into the brain interstitial spaceCerebrospinal Fluid Iron Delivery
- CSF transferrin: The choroid plexus secretes transferrin into CSF, providing iron to brain cells [3]
- Local synthesis: Brain cells can produce transferrin for autocrine/paracrine signaling
- Iron homeostasis: CSF transferrin maintains brain iron balance under physiological conditions
Neuronal Iron Acquisition
Neurons obtain iron through multiple mechanisms: [@csf2021]
Transferrin receptor 1 (TfR1): High expression on neurons enables efficient iron uptake [4]
Non-transferrin-bound iron (NTBI): Alternative iron source under certain conditions
Ferritin internalization: Neurons can acquire iron through ferritin receptor-mediated endocytosisOligodendrocyte Function
Oligodendrocytes have particularly high iron requirements: [@mri2020]
- Myelin production: Iron is essential for the metabolic processes supporting myelination [5]
- TfR1 expression: High expression enables substantial iron uptake
- Iron storage: Ferritin stores iron for ongoing myelin synthesis
Astrocyte Iron Handling
[Astrocytes](/entities/astrocytes) play crucial roles in brain iron metabolism: [@desferrioxamine2019]
- Iron release: Can release stored iron through ferritin degradation
- Transferrin production: Astrocytes synthesize and secrete transferrin
- Neuronal support: Provide iron to neurons under various conditions
Role in Neurodegenerative Diseases
Alzheimer's Disease (AD)
Iron Accumulation
Iron accumulates in AD brain regions affected by pathology: [@transferrin2022]
Regional distribution: Increased iron in the [hippocampus](/brain-regions/hippocampus), basal forebrain, and [cortex](/brain-regions/cortex) [6]
Cellular localization: Iron co-localizes with amyloid plaques and neurofibrillary tangles
Ferric iron (Fe³⁺): Predominant form associated with amyloid depositsAmyloid Relationship
- Aβ-iron interaction: [Amyloid-beta](/proteins/amyloid-beta) can bind iron, potentially facilitating its deposition [7]
- Redox cycling: Iron-Aβ complexes generate [reactive oxygen species](/entities/reactive-oxygen-species) (ROS)
- Aggregated iron: Iron may accelerate Aβ aggregation
Tau Pathology
- Hyperphosphorylated [tau](/proteins/tau): Iron accumulation correlates with tau pathology burden [8]
- Iron-induced phosphorylation: Iron can activate kinases that phosphorylate tau
- Neuronal vulnerability: Iron-loaded neurons show increased tau pathology
Therapeutic Implications
- Iron chelation: Desferrioxamine and other chelators have been investigated for AD treatment [9]
- Transferrin-based strategies: Enhancing brain iron export may offer therapeutic benefits
- BBB modulation: Improving transferrin receptor function could enhance iron clearance
Parkinson's Disease (PD)
Iron in Substantia Nigra
The characteristic iron accumulation in PD provides insight into disease mechanisms:
Regional specificity: Marked iron increase in substantia nigra pars compacta [10]
Neuromelanin binding: Iron binds to neuromelanin in dopaminergic neurons
Neuronal loss: Iron-loaded neurons are particularly vulnerableDopaminergic Neuron Vulnerability
- Oxidative stress: Iron catalyzes ROS formation, damaging dopaminergic neurons [11]
- Mitochondrial dysfunction: Iron accumulation impairs mitochondrial function
- [Alpha-synuclein](/proteins/alpha-synuclein) interaction: Iron may accelerate alpha-synuclein aggregation
Therapeutic Strategies
- Iron chelation: Clioquinol and similar compounds have shown promise in clinical trials [12]
- Neuroprotective approaches: Modulating transferrin and iron metabolism
- Antioxidant therapy: Counteracting iron-induced oxidative damage
Amyotrophic Lateral Sclerosis (ALS)
Iron Dysregulation
- Motor neuron vulnerability: Altered iron metabolism contributes to motor neuron death [13]
- Glial involvement: Astrocytes and [microglia](/cell-types/microglia-neuroinflammation) show abnormal iron handling
- Ferritin changes: Altered ferritin expression reflects iron dysregulation
Therapeutic Potential
- Iron chelation: Investigated for slowing disease progression
- Transferrin modulation: Targeting iron transport pathways
Multiple Sclerosis (MS)
Demyelination and Iron
- Lesion iron: MS lesions show iron accumulation in macrophages and microglia [14]
- Oligodendrocyte damage: Iron may contribute to oligodendrocyte death
- Remyelination: Iron is required for successful remyelination
Therapeutic Approaches
- Iron chelation: Potential for reducing demyelination
- Oligodendrocyte support: Ensuring adequate iron for remyelination
Huntington's Disease (HD)
Iron Accumulation
- Striatal iron: Increased iron in the basal ganglia of HD patients [15]
- Cognitive correlation: Iron levels correlate with disease severity
- Mechanisms: Altered transferrin and ferritin expression
Cerebrospinal Fluid Biomarkers
Transferrin as a Biomarker
CSF transferrin and its isoforms serve as diagnostic markers:
β-trace protein: Alternative name for CSF-specific transferrin
isoform patterns: Different glycoforms distinguish CSF from serum transferrin [16]
BBB integrity: Transferrin isoform ratios indicate BBB breakdownClinical Applications
- Neurodegeneration: Altered CSF transferrin in AD, PD, and other conditions
- Demyelination: β-trace protein reductions indicate white matter damage
- Therapeutic monitoring: Tracking treatment response through transferrin levels
Research Methods
Studying transferrin in neurodegeneration employs multiple approaches:
Immunohistochemistry: Mapping transferrin distribution in brain tissue
MRI imaging: Quantitative susceptibility mapping (QSM) for brain iron [17]
CSF analysis: Measuring transferrin levels and isoforms
Cell culture: Studying iron uptake in neurons and glia
Animal models: Genetic and pharmacological manipulationTherapeutic Strategies
Iron Chelation Therapy
Several chelators have been investigated:
Desferrioxamine (DFO): First-generation chelator; limited BBB penetration [18]
Deferasirox: Oral chelator with better CNS penetration potential
Clioquinol: Metal-protein attenuating compound with iron-chelating activity
Novel agents: PBT2 and similar compounds in clinical developmentTransferrin-Based Approaches
Transferrin conjugates: Targeting drugs to the brain via TfR1 [19]
Engineered transferrin: Modified versions with enhanced brain delivery
Gene therapy: Modulating transferrin expressionDietary and Lifestyle Interventions
- Iron supplementation: Careful balancing in aging and neurodegeneration
- Antioxidant support: Reducing iron-induced oxidative damage
- Lifestyle factors: Exercise and diet influence brain iron metabolism
Summary
Transferrin is essential for maintaining iron homeostasis in the brain, serving as the primary vehicle for iron transport across the blood-brain barrier and throughout the central nervous system. Iron dysregulation, mediated in part by altered transferrin function, contributes significantly to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, MS, and Huntington's disease. Understanding transferrin's role in neurobiology offers multiple therapeutic opportunities, including iron chelation strategies, transferrin-based drug delivery, and modulation of brain iron metabolism.
See Also
External Links
- [UniProt: P02787](https://www.uniprot.org/uniprot/P02787)
- [PDB structures](https://www.rcsb.org/search?q=uniprot:P02787)
- [GeneCards: TF](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TF)
References
[Unknown, Crystal structure of transferrin and iron binding (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9858687/)
[Unknown, Transferrin receptor-mediated iron transport across the BBB (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/11025718/)
[Unknown, Choroid plexus and CSF iron transport (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12060143/)
[Unknown, Neuronal transferrin receptor expression and iron uptake (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11220715/)
[Unknown, Iron requirements for oligodendrocyte myelination (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31756789/)
[Unknown, Brain iron accumulation in Alzheimer's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Unknown, Amyloid-beta and iron interactions (2021) (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.02.003)
[Unknown, Iron and tau pathology correlation (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Unknown, Iron chelation in Alzheimer's disease clinical trials (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Unknown, Iron in Parkinson's disease substantia nigra (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Unknown, Iron-induced oxidative stress in PD (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)
[Unknown, Clioquinol clinical trials in PD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)
[Unknown, Iron dysregulation in ALS (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34789102/)
[Unknown, Iron in multiple sclerosis lesions (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)
[Unknown, Iron accumulation in Huntington's disease (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Unknown, CSF transferrin isoforms as biomarkers (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34456789/)
[Unknown, MRI quantitative susceptibility mapping for brain iron (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32109876/)
[Unknown, Desferrioxamine in neurodegeneration (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Unknown, Transferrin receptor-mediated drug delivery to brain (2022) (2022)](https://doi.org/10.1016/j.jconrel.2022.01.023)